In vivo biodistribution of antihyperglycemic biopolymer-based nanoparticles for the treatment of type 1 and type 2 diabetes

Eur J Pharm Biopharm. 2017 Apr:113:88-96. doi: 10.1016/j.ejpb.2016.11.037. Epub 2016 Dec 19.

Abstract

This study aimed to assess the biodistribution of antihyperglycemic insulin-loaded alginate/dextran sulfate-based nanoparticles dual coated with chitosan and technetium-99m-albumin (99mTc-BSA) after oral administration. The oral administration of 50IU/kg insulin-loaded nanoparticles to type 1 diabetic rats showed prolonged antihyperglycemic effects up to 12h and relative pharmacological availability of 5.04% comparing to the subcutaneous administration. The oral antihyperglycemic effect was further compared between type 1 and type 2 diabetic models by the intraperitoneal glucose tolerance test, revealing that the effect lasted longer in the type 1 diabetic model. 99mTc-BSA revealed to be a good nanoparticles' tracer since there was no systemic absorption and 99mTc-BSA-nanoparticles were capable of increasing their residence time in the intestinal epithelium of balb-c mice when compared with 99mTc-BSA biodistribution. Thus, this biopolymeric-based delivery nanoparticulate system is a promising tool for the therapy of type 1 and type 2 diabetic individuals and prevention of T1D.

Keywords: Biodistribution; Insulin; Oral delivery; Type 1 diabetes; Type 2 diabetes.

MeSH terms

  • Animals
  • Biopolymers*
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 2 / drug therapy
  • Glucose Tolerance Test
  • Hypoglycemic Agents / pharmacokinetics*
  • Hypoglycemic Agents / therapeutic use
  • Insulin / administration & dosage
  • Male
  • Microscopy, Electron, Scanning / methods
  • Nanoparticles*
  • Rats
  • Rats, Wistar
  • Streptozocin
  • Tissue Distribution

Substances

  • Biopolymers
  • Hypoglycemic Agents
  • Insulin
  • Streptozocin